- Home
- BCTX vs EVAX Comparison
BCTX vs EVAX Comparison
Compare BCTX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- EVAX
- Stock Information
- Founded
- BCTX 2014
- EVAX 2008
- Country
- BCTX Canada
- EVAX Denmark
- Employees
- BCTX N/A
- EVAX N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCTX Health Care
- EVAX Health Care
- Exchange
- BCTX Nasdaq
- EVAX Nasdaq
- Market Cap
- BCTX 13.7M
- EVAX 15.1M
- IPO Year
- BCTX N/A
- EVAX 2021
- Fundamental
- Price
- BCTX $0.81
- EVAX $2.58
- Analyst Decision
- BCTX Strong Buy
- EVAX Strong Buy
- Analyst Count
- BCTX 1
- EVAX 2
- Target Price
- BCTX $32.00
- EVAX $10.00
- AVG Volume (30 Days)
- BCTX 2.5M
- EVAX 88.8K
- Earning Date
- BCTX 06-16-2025
- EVAX 08-13-2025
- Dividend Yield
- BCTX N/A
- EVAX N/A
- EPS Growth
- BCTX N/A
- EVAX N/A
- EPS
- BCTX N/A
- EVAX N/A
- Revenue
- BCTX N/A
- EVAX $3,293,000.00
- Revenue This Year
- BCTX N/A
- EVAX N/A
- Revenue Next Year
- BCTX N/A
- EVAX N/A
- P/E Ratio
- BCTX N/A
- EVAX N/A
- Revenue Growth
- BCTX N/A
- EVAX 2555.64
- 52 Week Low
- BCTX $0.69
- EVAX $1.20
- 52 Week High
- BCTX $29.40
- EVAX $17.75
- Technical
- Relative Strength Index (RSI)
- BCTX 14.56
- EVAX 55.34
- Support Level
- BCTX $0.69
- EVAX $2.53
- Resistance Level
- BCTX $3.00
- EVAX $2.71
- Average True Range (ATR)
- BCTX 0.20
- EVAX 0.15
- MACD
- BCTX -0.15
- EVAX -0.00
- Stochastic Oscillator
- BCTX 4.75
- EVAX 62.84
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.